Top Stories
Britain’s Prince Charles to open new AstraZeneca research centre
Published by Jessica Weisman-Pitts
Posted on November 23, 2021
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Jessica Weisman-Pitts
Posted on November 23, 2021
CAMBRIDGE, England (Reuters) -Britain’s Prince Charles will formally open a new 1 billion pound ($1.3 billion) AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
AstraZeneca has supplied two billion doses of its COVID-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against COVID-19 to market.
But while the company is setting up a separate division for vaccine and antibody therapies in light of the coronavirus pandemic, it has also beefed up other areas of research
Earlier this year, AstraZeneca completed the $39 billion purchase of rare-disease specialist Alexion.
“Our new Discovery Centre in Cambridge… will allow us to break new boundaries in the understanding of disease biology, bring life-changing medicines to patients and power the next stage of our company’s growth,” Chief Executive Pascal Soriot said in a statement.
Prince Charles, son of Queen Elizabeth and heir to the throne, will take a walking tour of the centre and give a short address at the opening.
The plans for AstraZeneca’s new headquarters and large R&D campus in Cambridge were unveiled in 2013, but its costs and timeframe have exceeded the initial estimate of 330 million pounds and an aimed completion date of 2016.
AstraZeneca, which has a large portfolio of treatments for diseases such as cancer, heart disease and diabetes, said the centre would support research into specialised medicines and next-generation therapeutics, including gene-editing and cell therapies.
“We will have advances that could come to the clinic in the next three, four years, that can lead to really effective new drugs in various aspects of treating cancer,” Dr Susan Galbraith, AstraZeneca’s Executive Vice President, Oncology Research & Development, told Reuters in an interview.
“I’m very optimistic about the fact that we can make a big difference to this disease in the coming decade”
($1 = 0.7454 pounds)
(Reporting by Alistair SmoutAditional reporting by Ludwig Burger in FrankfurtEditing by Mark Potter and Louise Heavens)
CAMBRIDGE, England (Reuters) -Britain’s Prince Charles will formally open a new 1 billion pound ($1.3 billion) AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
AstraZeneca has supplied two billion doses of its COVID-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against COVID-19 to market.
But while the company is setting up a separate division for vaccine and antibody therapies in light of the coronavirus pandemic, it has also beefed up other areas of research
Earlier this year, AstraZeneca completed the $39 billion purchase of rare-disease specialist Alexion.
“Our new Discovery Centre in Cambridge… will allow us to break new boundaries in the understanding of disease biology, bring life-changing medicines to patients and power the next stage of our company’s growth,” Chief Executive Pascal Soriot said in a statement.
Prince Charles, son of Queen Elizabeth and heir to the throne, will take a walking tour of the centre and give a short address at the opening.
The plans for AstraZeneca’s new headquarters and large R&D campus in Cambridge were unveiled in 2013, but its costs and timeframe have exceeded the initial estimate of 330 million pounds and an aimed completion date of 2016.
AstraZeneca, which has a large portfolio of treatments for diseases such as cancer, heart disease and diabetes, said the centre would support research into specialised medicines and next-generation therapeutics, including gene-editing and cell therapies.
“We will have advances that could come to the clinic in the next three, four years, that can lead to really effective new drugs in various aspects of treating cancer,” Dr Susan Galbraith, AstraZeneca’s Executive Vice President, Oncology Research & Development, told Reuters in an interview.
“I’m very optimistic about the fact that we can make a big difference to this disease in the coming decade”
($1 = 0.7454 pounds)
(Reporting by Alistair SmoutAditional reporting by Ludwig Burger in FrankfurtEditing by Mark Potter and Louise Heavens)